UB-311
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
UB-311 is a vaccine targeting β-amyloid and hence anti-amyloid agent which is under development for the treatment of Alzheimer's disease. It is under development by Vaxxinity (delisted from stock market in May 2024). Meningoencephalitis has been described as a possible side effect of the drug. As of February 2024, the drug is in phase 2 clinical trials. In May 2022, UB-311 received fast-track designation for Alzheimer's disease from the United States Food and Drug Administration (FDA).
UB-311 is a vaccine targeting β-amyloid and hence anti-amyloid agent which is under development for the treatment of Alzheimer's disease. It is under development by Vaxxinity (delisted from stock market in May 2024). Meningoencephalitis has been described as a possible side effect of the drug. As of February 2024, the drug is in phase 2 clinical trials. In May 2022, UB-311 received fast-track designation for Alzheimer's disease from the United States Food and Drug Administration (FDA).
References
Text derived from https://en.wikipedia.org/w/index.php?oldid=1374092844 under CC BY-SA 4.0; modifications have been made.